α-interferon 2a and 13-cis-retinoic acid for the treatment of metastatic renal cell carcinoma

Internal Medicine Journal

Volumn 32, Issue 4, 2002, Pages 158-162

  Wong, M ^a   Goldstein, D ^b   Woo, H ^a   Testa, G ^a   Gurney, H ^a  

^a WESTMEAD HOSPITAL   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

interferon 2a; 13 cis retinoic acid; Metastatic; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON DERIVATIVE; ISOTRETINOIN; RECOMBINANT ALPHA2A INTERFERON;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; IMPOTENCE; KIDNEY CARCINOMA; KIDNEY METASTASIS; LETHARGY; MALE; NAUSEA; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RETINOIC ACID SYNDROME; SIDE EFFECT; SKIN TOXICITY; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; BIOPSY, NEEDLE; CARCINOMA, RENAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERFERON ALFA-2A; ISOTRETINOIN; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0036965852     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1444-0903.2001.00184.x     Document Type: Article

References (19)

1. The Cancer Council NSW. Cancer in NSW: incidence and mortality. Sydney: NSW Central Cancer Registry; 1999.
2. deKernion JB, Ramming KP, Smith RB. The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol 1978; 120: 148-52.
3. Yagoda A. Chemotherapy of renal cell carcinoma. Semin Urol 1989; 7: 199-206.
4. Rauh S, Duhem C, Ries F et al. Spontaneous regression of pulmonary metastases in renal cancer. Bull Soc Sci Med Grand Duche Luxemb 1998; 135: 39-42.
5. Bukowski R. Immunologic Response to Renal Cancer and the Therapeutic Role of Interleukin-2. In: American Society of Clinical Oncology: 2000 Educational Book. Alexandria, VA: American Society of Clinical Oncology; 2000; 651-9.
6. Medical Research Council Renal Cancer Collaborators. Interferon-a and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999; 353; 14-17.
7. Hong WK, Lippman SM, Itri LM et al. Prevention of second primary tumours with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990; 323: 795-801.
8. Lippman SM, Parkinson DR, Itri LM et al. 13-cis-Retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 1992; 84: 235-41.
9. Lippman SM, Kavanagh JJ, Paredes-Espinoza M et al. 13-cis-Retinoic acid and interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 1992; 84: 241-5.
10. Motzer RJ, Schwartz L, Law TM et al. Interferon alpha-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumour activity in a phase II trial and interactions in vitro. J Clin Oncol 1995; 13: 1950-7.
11. Wirth MP. Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 1993; 20: 283-95.
12. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
13. Motzer RJ, Mazumdar M, Bacik J et al. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18: 1928-35.
14. Motzer RJ, Murphy BA, Bacik J et al. Phase III trial of interferon alfa-2a with or without 13-cis-reinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18: 2972-2980.
15. Pyrhonen S, Salminen E, Ruutu M et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17: 2859-67.
16. Coppin C, Porzsolt F, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer (Cochrane Review). The Cochrane Library, Issue no. 2; 2001. Available from: URL: http://www.cochrane.org/cochrane/revabstr/ab001425.htm
17. Gleave ME, Elhilali M, Fradet Y et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med 1998; 338: 1265-71.
18. Childs R. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750-8.
19. Kugler A. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000; 6: 332-6.